Overview
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
Status:
Terminated
Terminated
Trial end date:
2011-02-01
2011-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To assess the efficacy of oral aliskiren as a therapy for diabetic macular edemaPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis Pharmaceuticals
Criteria
Inclusion criteria:- Type 1 or type 2 diabetes
- Diabetic macular edema
Exclusion criteria:
- Recent intra-ocular surgery in the study eye (e.g., cataract surgery in the last 6
months)
- Recent laser photocoagulation in the study eye
- Recent treatment with Avastin, Lucentis, or intravitreal corticosteroids in the study
eye
Other protocol-defined inclusion/exclusion criteria applied